CytoPherx develops a proprietary Selective Cytopheretic Device (SCD) that is added to the renal replacement circuit to modulate acute systemic inflammation in ICU patients with kidney injury. The company is clinical-stage and pursuing U.S. regulatory approval to commercialize its anti-inflammatory therapy for acute kidney injury. Management reports early trials showing potential mortality reductions of as much as 15% in critically ill patients. CytoPherx has initiated a 344-patient pivotal trial across leading U.S. nephrologists and institutions, with a primary endpoint of reduced mortality through day 60 and secondary evaluations including severe sepsis, ARDS, and long-term dialysis dependence. The company says the target population represents over 2.7 million hospitalized U.S. patients diagnosed with acute renal failure annually, with roughly 160,000 receiving Continuous Renal Replacement Therapy, a multi-billion dollar market opportunity. CytoPherx was founded in July 2007 and is headquartered in Ann Arbor, Michigan. CytoPherx develops hollow-fiber dialysis filters designed to isolate and deactivate white blood cells in patients’ bloodstreams to treat renal failure and inflammation from cardiopulmonary bypass. The company is a University of Michigan spinoff, founded in 2007 and previously known as Nephrion Inc., based in Ann Arbor, Mich. The recent funding will support a clinical trial for its filters; CytoPherx began enrolling patients last month and expects to complete enrollment by the end of June. The current financing is part of an anticipated $7.5M Series B, with $5M already raised. The new funds are structured as equity, debt and warrants and were sourced from five investors. To date, the company has raised $12M in total lifetime funding.

Total raised

$39M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2012